Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 19.91 billion. The enterprise value is 10.40 billion.

Market Cap	19.91B
Enterprise Value	10.40B

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	161.97M
Shares Outstanding	n/a
Shares Change (YoY)	+41.51%
Shares Change (QoQ)	+10.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.65M

Valuation Ratios

The trailing PE ratio is 2.03.

PE Ratio	2.03
Forward PE	n/a
PS Ratio	0.78
PB Ratio	-12.88
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.18, with an EV/FCF ratio of -2.59.

EV / Earnings	1.06
EV / Sales	0.44
EV / EBITDA	1.18
EV / EBIT	1.30
EV / FCF	-2.59

Financial Position

The company has a current ratio of 2.06

Current Ratio	2.06
Quick Ratio	1.78
Debt / Equity	n/a
Debt / EBITDA	0.49
Debt / FCF	-1.16
Interest Coverage	19.50

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	19.97%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	48.55%
Revenue Per Employee	26.94M
Profits Per Employee	10.28M
Employee Count	952
Asset Turnover	0.95
Inventory Turnover	40.12

Taxes

In the past 12 months, Novavax has paid 200.75 million in taxes.

Income Tax	200.75M
Effective Tax Rate	2.01%

Stock Price Statistics

The stock price has decreased by -51.00% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.00%
50-Day Moving Average	130.93
200-Day Moving Average	171.59
Relative Strength Index (RSI)	42.69
Average Volume (20 Days)	551

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.00

Income Statement

In the last 12 months, Novavax had revenue of MXN 25.65 billion and earned 9.78 billion in profits. Earnings per share was 60.79.

Revenue	25.65B
Gross Profit	14.97B
Operating Income	8.64B
Pretax Income	9.98B
Net Income	9.78B
EBITDA	9.56B
EBIT	8.64B
Earnings Per Share (EPS)	60.79

Full Income Statement

Balance Sheet

The company has 14.95 billion in cash and 4.67 billion in debt, giving a net cash position of 10.28 billion.

Cash & Cash Equivalents	14.95B
Total Debt	4.67B
Net Cash	10.28B
Net Cash Per Share	n/a
Equity (Book Value)	-1.55B
Book Value Per Share	-9.55
Working Capital	9.11B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.87 billion and capital expenditures -151.23 million, giving a free cash flow of -4.02 billion.

Operating Cash Flow	-3.87B
Capital Expenditures	-151.23M
Free Cash Flow	-4.02B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 58.37%, with operating and profit margins of 33.69% and 38.14%.

Gross Margin	58.37%
Operating Margin	33.69%
Pretax Margin	38.93%
Profit Margin	38.14%
EBITDA Margin	37.25%
EBIT Margin	33.69%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-41.51%
Shareholder Yield	n/a
Earnings Yield	49.15%
FCF Yield	-20.19%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -1.71 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.71
Piotroski F-Score	5